![T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | Nature Medicine T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-01194-5/MediaObjects/41591_2020_1194_Fig1_HTML.png)
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | Nature Medicine
![Muse's Matt Bellamy: 'I've got to an age where I'm not so titillated by disaster' | Muse | The Guardian Muse's Matt Bellamy: 'I've got to an age where I'm not so titillated by disaster' | Muse | The Guardian](https://i.guim.co.uk/img/media/1032686ee87d5e2d34022e8110048574d48069e7/0_116_3500_2101/master/3500.jpg?width=700&quality=85&auto=format&fit=max&s=de79a788a1f93b93127e9c4b68c09995)
Muse's Matt Bellamy: 'I've got to an age where I'm not so titillated by disaster' | Muse | The Guardian
![Muse's Matt Bellamy: 'I've got to an age where I'm not so titillated by disaster' | Muse | The Guardian Muse's Matt Bellamy: 'I've got to an age where I'm not so titillated by disaster' | Muse | The Guardian](https://i.guim.co.uk/img/media/6565e7498763e7f9a74ad033a33eb95c36ee2595/0_21_4000_2400/master/4000.jpg?width=445&dpr=1&s=none)
Muse's Matt Bellamy: 'I've got to an age where I'm not so titillated by disaster' | Muse | The Guardian
![Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-020-01179-4/MediaObjects/41591_2020_1179_Fig1_HTML.png)
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine
![Covid-19: U.S. Officials Pledge Almost $200 Million to Track Variants as Lawmakers Push for More - The New York Times Covid-19: U.S. Officials Pledge Almost $200 Million to Track Variants as Lawmakers Push for More - The New York Times](https://static01.nyt.com/images/2021/02/17/us/17virus-briefing-biden-100-days-100m-shots-goal/merlin_183846327_42815cab-24ee-4956-b5f6-de1d5586e64f-videoSixteenByNine3000.jpg?year=2021&h=1688&w=3000&s=24efcfd96f9953d8af91da7153a3376728082f86c0a8501e708e0f3b6800a1f5&k=ZQJBKqZ0VN&tw=1)
Covid-19: U.S. Officials Pledge Almost $200 Million to Track Variants as Lawmakers Push for More - The New York Times
![Covid-19: U.S. Officials Pledge Almost $200 Million to Track Variants as Lawmakers Push for More - The New York Times Covid-19: U.S. Officials Pledge Almost $200 Million to Track Variants as Lawmakers Push for More - The New York Times](https://static01.nyt.com/images/2021/02/17/us/17STORM-vaccine/merlin_183794634_958967ef-8ac0-48de-a67f-edc57fbe6db7-superJumbo.jpg)
Covid-19: U.S. Officials Pledge Almost $200 Million to Track Variants as Lawmakers Push for More - The New York Times
![Muse's Matt Bellamy: 'I've got to an age where I'm not so titillated by disaster' | Muse | The Guardian Muse's Matt Bellamy: 'I've got to an age where I'm not so titillated by disaster' | Muse | The Guardian](https://i.guim.co.uk/img/media/f7cf89906b503a1029b18aa3dbb68d91aeac2502/59_47_4258_2555/500.jpg?quality=85&auto=format&fit=max&s=a9371674d86884fa4e7e66cb1f965100)
Muse's Matt Bellamy: 'I've got to an age where I'm not so titillated by disaster' | Muse | The Guardian
![Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial - The Lancet Infectious Diseases Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/fdb79058-8d5e-4759-a45a-924689657428/gr1.jpg)
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial - The Lancet Infectious Diseases
![Keith Spera's Sound Check: Muse, Journey, Third Eye Blind and more music in New Orleans June 8-14, 2017 | Keith Spera | nola.com Keith Spera's Sound Check: Muse, Journey, Third Eye Blind and more music in New Orleans June 8-14, 2017 | Keith Spera | nola.com](https://bloximages.newyork1.vip.townnews.com/nola.com/content/tncms/assets/v3/editorial/9/6e/96e15448-b273-5fd1-8e6b-797f95fe9181/5cde1f426d1b5.image.jpg?crop=1763%2C926%2C0%2C124&resize=1200%2C630&order=crop%2Cresize)